Pharmacodynamic Evaluation of Extending the Administration Time of Meropenem using a Monte Carlo Simulation

AUTOR(ES)

Lomaestro, Ben M.

FONTE

American Society for Microbiology

RESUMO

A Monte Carlo simulation demonstrated that 1 g of meropenem (MEM) every 8 h (q8h) (3-h infusion) has a higher target attainment rate against Pseudomonas aeruginosa than either 500 mg of MEM q8h (3-h infusion) or 0.5 g of imipenem-cilastatin (I-C) q6h (1-h infusion). For other pathogens, 500 mg of MEM q8h was equivalent or superior to I-C.

Documentos Relacionados

• Neutron tomography using projection data obtained by Monte Carlo simulation for nondestructive evaluation
• APREÇAMENTO DE OPÇÕES EXÓTICAS: UMA ABORDAGEM PELA SIMULAÇÃO DE MONTE-CARLO
• Monte Carlo simulation for the evaluation of measurement uncertainty of pharmaceutical certified reference materials
• Theoretical Studies of Concentrated Aqueous Urea Solutions Using Computacional Monte Carlo Simulation
• Pharmacodynamic Profiling of Piperacillin in the Presence of Tazobactam in Patients through the Use of Population Pharmacokinetic Models and Monte Carlo Simulation